NVX-COV2373 (NOVAVAX)

Zendal biopharmaceutical group, through its subsidiary Biofabri, has been chosen by the American company Novavax as their European partner for the industrial manufacturing of its vaccine antigen against  COVID-19 in the whole of the European Union.

Novavax Inc., a biotechnological company specialised in developing state-of-the-art vaccines for serious infectious diseases is developing a vaccine candidate against COVID-19, the NVX-CoV2373, that is being produced in tandem with clinical trials so that once the desired results with the subsequent authorisation are obtained, it can be introduced into the market as soon as possible.

The signing of this agreement puts us at the forefront of biotechnological companies as the only Spanish one, and of the few in Europe at the moment, to begin the manufacturing process of one of the vacines to combat COVID.

evolution

The signing of this agreement puts us at the forefront of biotechnological companies as the only Spanish one, and of the few in Europe at the moment, to begin the manufacturing process of one of the vacines to combat COVID.

muestras

For more details

Contact us